10X Genomics, Inc. (TXG)
Stock Price Chart
Key Info
| Market Cap | 15.00B |
| Revenue (ttm) | 251.31M |
| Net Income (ttm) | -78.05M |
| Shares Out | 78.05M |
| EPS (ttm) | -5.41 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | Oct 26, 2020 |
| Last Price | $141.15 |
| Previous Close | $142.27 |
| Change ($) | -1.12 |
| Change (%) | -0.79% |
| Day's Open | 142.00 |
| Day's Range | 139.53 - 144.56 |
| Day's Volume | 479,090 |
| 52-Week Range | 48.78 - 166.31 |
More Stats
| Market Cap | 15.00B |
| Enterprise Value | 14.65B |
| Earnings Date (est) | Nov 10, 2020 |
| Ex-Dividend Date | n/a |
| Shares Outstanding | 78.05M |
| Float | 64.54M |
| EPS (basic) | -0.55 |
| EPS (diluted) | -5.41 |
| FCF / Share | -0.46 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
| Payout Ratio | n/a |
| Shares Short | 1.88M |
| Short Ratio | 1.82 |
| Short % of Float | 2.91% |
| Beta | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| P/FCF Ratio | n/a |
| PS Ratio | 59.68 |
| PB Ratio | 39.78 |
| Revenue | 251.31M |
| Operating Income | -76.48M |
| Net Income | -78.05M |
| Free Cash Flow | -45.92M |
| Net Cash | 344.52M |
| Net Cash / Share | 3.24 |
| Gross Margin | 85.18% |
| Operating Margin | -30.43% |
| Profit Margin | -31.10% |
| FCF Margin | -18.27% |
| ROA | -9.13% |
| ROE | -38.39% |
| ROIC | -63.70% |
Analyst Summary
Analyst Consensus: Buy
Financial Performance
Financial Overview
| Year | 2019 | 2018 | 2017 |
|---|---|---|---|
| Revenue | 246 | 146 | 71.09 |
| Revenue Growth | 68.06% | 105.83% | - |
| Gross Profit | 185 | 118 | 60.53 |
| Operating Income | -30.57 | -111 | -18.38 |
| Net Income | -31.25 | -112 | -18.76 |
| Shares Outstanding | 39.09 | 13.39 | 11.59 |
| Earnings Per Share | -0.80 | -8.40 | -1.62 |
| Operating Cash Flow | 34.63 | -76.41 | -10.70 |
| Capital Expenditures | -42.74 | -6.28 | -3.76 |
| Free Cash Flow | -8.12 | -82.69 | -14.46 |
| Cash & Equivalents | 476 | 70.09 | 47.86 |
| Total Debt | 29.72 | 29.68 | 10.56 |
| Net Cash / Debt | 447 | 40.41 | 37.30 |
| Assets | 606 | 124 | 75.61 |
| Liabilities | 186 | 101 | 29.70 |
| Book Value | 420 | -220 | -113 |
Company Profile
Company Details
| Full Name | 10X Genomics, Inc. |
| Country | United States |
| Employees | 713 |
| CEO | Serge Saxonov |
Stock Information
| Ticker Symbol | TXG |
| Stock Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Health Information Services |
| Unique Identifier | NASDAQ: TXG |
| IPO Date | September 12, 2019 |
Description
10x Genomics, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. Its company offers chromium instruments, enzymes, microfluidic chips, slides, reagents, and other consumable products. The company's single cell solution runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell ATAC for measuring epigenetics, including the physical organization of DNA; single cell CNV for measuring cellular heterogeneity through DNA changes, such as copy number variation; and visium spatial gene expression solution that measures the spatial gene expression patterns across a tissue sample. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10X Genomics, Inc. in November 2014. 10x Genomics, Inc. was founded in 2012 and is headquartered in Pleasanton, California.